Phase II Study in Adult and Young Adult Patients With DSRCT
Status:
RECRUITING
Trial end date:
2030-10-01
Target enrollment:
Participant gender:
Summary
This study involves patients with the same type of advanced cancer as you-DSRCT, a very rare soft tissue sarcoma.
Patients participating in this study have DSRCT that has spread locally or to other parts of the body and can no longer be surgically removed without causing significant harm.
Participants will receive a combination of lurbinectedin and irinotecan. Treatment will continue until the tumor progresses further, severe side effects occur, or either patient or investigator decision.
In addition, patients may participate in an optional biological study. The study will analyze the tumor's genes and the molecules related to them. By studying genes and their products, we can better understand the behavior of the tumor and how the body responds to therapies.